Mantle cell lymphoma: New treatments targeted to the biology

被引：6

作者：

Bertoni, F

Ghielmini, M

Cavalli, F

Cotter, FE

Zucca, E ^{[1
]}

机构：

[1] Osped San Giovanni Bellinzona, Div Med Oncol, Oncol Inst So Switzerland, CH-6500 Bellinzona, Switzerland

[2] Barts & London Queen Marys Sch Med & Dent, Dept Expt Hematol, London, England

来源：

CLINICAL LYMPHOMA | 2002年 / 3卷 / 02期

关键词：

monoclonal antibodies; rituximab; tositumomab; ibritumomab; apoptosis; CD20; proteasome inhibitors;

D O I：

10.3816/CLM.2002.n.014

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Mantle cell lymphoma (MCL) represents a distinct lymphoma subtype. The prognosis of patients with MCL is the poorest among lymphoma patients and the response to conventional treatments is inadequate. New approaches targeted to the biology of MCL and the genetics underlying the disease are being studied. Monoclonal antibodies directed at molecules expressed on MCL cells are already used in the clinical setting. This article reviews the literature on these and other new possible treatment modalities.

引用

页码：90 / 96

页数：7

共 113 条

[1] Adams J, 1999, CANCER RES, V59, P2615
[2] Proteasome inhibition: a new strategy in cancer treatment
Adams, J
Palombella, VJ
Elliott, PJ
[J]. INVESTIGATIONAL NEW DRUGS, 2000, 18 (02) : 109 - 121
[3] Alas S, 2000, ANTICANCER RES, V20, P2961
[4] Alas S, 2001, CLIN CANCER RES, V7, P709
[5] Failure of immunologic purging in mantle cell lymphoma assessed by polymerase chain reaction detection of minimal residual disease
Andersen, NS
Donovan, JW
Borus, JS
Poor, CM
Neuberg, D
Aster, JC
Nadler, LM
Freedman, AS
Gribben, JG
[J]. BLOOD, 1997, 90 (10) : 4212 - 4221
[6] Auer RL, 2001, BLOOD, V98, p808A
[7] Is there an increased rate of additional malignancies in patients with mantle cell lymphoma?
Barista, I
Cabanillas, F
Romaguera, JE
Khouri, IF
Yang, Y
Smith, TL
Strom, SS
Medeiros, LJ
Hagemeister, FB
[J]. ANNALS OF ONCOLOGY, 2002, 13 (02) : 318 - 322
[8] Batova A, 1999, CANCER RES, V59, P1492
[9] RETRACTED: High-dose myeloablative radioimmunotherapy of mantle cell non-Hodgkin lymphoma with the iodine-131-labeled chimeric anti-CD20 antibody C2B8 and autologous stem cell support - Results of a pilot study (Retracted Article)
Behr, TM
Griesinger, F
Riggert, J
Gratz, S
Béhé, M
Kaufmann, CC
Wörmann, B
Brittinger, G
Becker, W
[J]. CANCER, 2002, 94 (04) : 1363 - 1372
[10] Complement-mediated cell death induced by rituximab in B-cell lymphoproliferative disorders is mediated in vitro by a caspase-independent mechanism involving the generation of reactive oxygen species
Bellosillo, B
Villamor, N
López-Guillermo, A
Marcé, S
Esteve, J
Campo, E
Colomer, D
Montserrat, E
[J]. BLOOD, 2001, 98 (09) : 2771 - 2777

← 1 2 3 4 5 6 7 8 9 10 →